Core Transcriptional Regulatory Circuit Controlled by the TAL1 Complex in T-Cell Acute Lymphoblastic Leukemia,

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 3453-3453
Author(s):  
Takaomi Sanda ◽  
Lee N Lawton ◽  
M Inmaculada Barrasa ◽  
Zi Peng Fan ◽  
Yebin Ahn ◽  
...  

Abstract Abstract 3453 Aberrant expression of TAL1 is one of the most frequent abnormalities in T-cell acute lymphoblastic leukemia (T-ALL), yet little is known about the transcriptional network controlled by this oncogenic transcription factor, posing a major obstacle to understanding T-ALL pathogenesis. Here we identify the core transcriptional regulatory circuit controlled by TAL1 and its regulatory partners HEB, E2A, GATA3 and RUNX1 in T-ALL cells. We determined direct transcriptional targets of TAL1 and its regulatory partners by ChIP-seq analysis, and found that TAL1 binds to the majority of HEB- and E2A-enriched regions and that these commonly bound regions are frequently overlapping with the GATA3- and RUNX1-enriched regions. We found that TAL1 forms an interconnected auto-regulatory loop with its partners, which likely contribute to the sustained upregulation of its direct target genes. TAL1 core regulatory circuit activates genes involved in T-cell development and hematopoesis. Microarray gene expression analysis revealed that TAL1 and GATA3 predominantly act as positive regulators of the expression of their direct target genes in T-ALL. Importantly, we found the MYB oncogenic transcription factor is directly activated by the TAL1 complex and positively regulates many of the same target genes, thus forming a feed-forward positive regulatory loop that further promotes the TAL1-regulated oncogenic program. Moreover, we found that a specific subset of TAL1 target genes are oppositely regulated by TAL1 and its obligate partner proteins E2A and HEB, uncovering a leukemogenic pattern that previously emerged from studies in murine models. These findings underscore the importance of TAL1 as a critical regulator of an aberrant gene expression program in T-ALL, and indicate how these networks maintain the malignant state in thymocytes. Disclosures: No relevant conflicts of interest to declare.

Cancer Cell ◽  
2012 ◽  
Vol 22 (2) ◽  
pp. 209-221 ◽  
Author(s):  
Takaomi Sanda ◽  
Lee N. Lawton ◽  
M. Inmaculada Barrasa ◽  
Zi Peng Fan ◽  
Holger Kohlhammer ◽  
...  

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 676-676
Author(s):  
Giusy Della Gatta ◽  
Teresa Palomero ◽  
Maria Luisa Sulis ◽  
Xavier Solé ◽  
Wei Keat Lim ◽  
...  

Abstract Abstract 676 T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy associated with the activation of transcription factor oncogenes. TLX1/HOX11 was originally isolated from the recurrent t(10;14)(q24;q11) translocation and is aberrantly expressed in 5% to 10% of pediatric and up to 30% of adult T-ALL. The TLX3/HOX11L2 oncogene is closely related to TLX1 and is activated by the cryptic t(5;14)(q35;q32) chromosomal translocation in 25% of pediatric T-ALLs. TLX1 and TLX3 positive T-ALLs have a distinct gene expression profile resembling that of thymocytes blocked at the early double-positive stage of development, suggesting that aberrant expression of TLX1 and TLX3 interferes with critical transcriptional regulatory networks that control cell proliferation, differentiation and survival during T-cell development. However, the identity of such oncogenic pathways and the mechanisms through which they operate are still largely unknown. Here we used an integrated systems biology approach to elucidate the transcriptional regulatory networks controlled by aberrant expression of TLX1 and TLX3 in T-ALL. Towards this goal, we performed gene expression profiling studies and ChIP-on-chip analysis of TLX1 and TLX3 direct target genes in leukemic lymphoblasts. ChIP-on-chip analysis of TLX1 direct target genes identified 5,550 promoters bound by TLX1 in ALL-SIL T-ALL cells with a significance cutoff of P <0.0001. Similarly, ChIP-on-chip analysis of TLX3 direct target genes identified 7,183 promoters bound by this transcription factor oncogene in HPB-ALL cells at the P <0.0001 significance level. Most notably, TLX1 direct targets showed >75% overlap with the TLX3 ChIP-on-chip target genes (P<10E-16), suggesting a common mechanism of action for TLX1 and TLX3 in T-cell transformation. Notably, inhibition of TLX1 expression by shRNA in the ALL-SIL cell line resulted in global transcriptional upregulation of TLX1 direct target genes, establishing a direct connection between TLX1 binding and promoter regulation and defining TLX1 as a transcriptional repressor in T-ALL. Following on these results, we used Affymetrix arrays to analyze the pattern of gene expression associated with TLX1 and TLX3 in a series of 82 primary T-ALLs. This analysis identified a gene expression signature dominated by genes downregulated in TLX1 and TLX3 positive cases, which was markedly and significantly enriched in TLX1 and TLX3 direct targets (P <0.0001). These results define the core transcriptional program controlled by TLX1 and TLX3 in T-cell transformation and open two possible scenarios. First, most, if not all, TLX1 and TLX3 target genes may play an equivalent role downstream of these transcription factor oncogenes to modulate multiple functional pathways some of which will contribute to T-cell transformation. Alternatively, TLX1 and TLX3 target genes may be organized in hierarchical transcriptional regulatory modules. This second model would be characterized by the presence of master regulator genes with a high level of network connectivity and the capacity to redundantly control multiple genes in the core transcriptional program controlled by TLX1 and TLX3. In order to annotate the functional relevance of TLX1 and TLX3 direct target genes we used ARACNe, an algorithm for the reverse engineering of transcriptional networks, in a series of 228 primary T-ALL samples analyzed using Affymetrix U133 plus 2.0 expression arrays. This analysis established that the transcriptional network controlled by TLX1 and TLX3 has a hierarchical scale free structure in which a limited number of master regulator genes show a high level of connectivity. Notably, this structure defines RUNX1, a master regulator of hematopoietic and T-cell development, as the most prominent direct target gene controlled by TLX1 and TLX3 in T-ALL. Consistent with these results, integrative analysis of expression signatures in human (n=82) and mouse (n=55) T-ALLs, identified Runx1 downregulation as a prominent feature associated with aberrant expression of TLX1. Overall, these results identify the transcriptional regulatory program controlled by TLX1 and TLX3 in T-ALL, establish the role of TLX1 and TLX3 as transcriptional repressors in T-cell transformation and point to a prominent role of RUNX1 downregulation in the pathogenesis of T- ALL. Disclosures: No relevant conflicts of interest to declare.


Cells ◽  
2020 ◽  
Vol 9 (7) ◽  
pp. 1726
Author(s):  
Valentina Saccomani ◽  
Angela Grassi ◽  
Erich Piovan ◽  
Deborah Bongiovanni ◽  
Ludovica Di Martino ◽  
...  

T-cell acute lymphoblastic leukemia (T-ALL) is a rare, aggressive disease arising from T-cell precursors. NOTCH1 plays an important role both in T-cell development and leukemia progression, and more than 60% of human T-ALLs harbor mutations in components of the NOTCH1 signaling pathway, leading to deregulated cell growth and contributing to cell transformation. Besides multiple NOTCH1 target genes, microRNAs have also been shown to regulate T-ALL initiation and progression. Using an established mouse model of T-ALL induced by NOTCH1 activation, we identified several microRNAs downstream of NOTCH1 activation. In particular, we found that NOTCH1 inhibition can induce miR-22-3p in NOTCH1-dependent tumors and that this regulation is also conserved in human samples. Importantly, miR-22-3p overexpression in T-ALL cells can inhibit colony formation in vitro and leukemia progression in vivo. In addition, miR-22-3p was found to be downregulated in T-ALL specimens, both T-ALL cell lines and primary samples, relative to immature T-cells. Our results suggest that miR-22-3p is a functionally relevant microRNA in T-ALL whose modulation can be exploited for therapeutic purposes to inhibit T-ALL progression.


PLoS ONE ◽  
2019 ◽  
Vol 14 (12) ◽  
pp. e0224652
Author(s):  
Mingmin Wang ◽  
Jinquan Wen ◽  
Yuxia Guo ◽  
Yali Shen ◽  
Xizhou An ◽  
...  

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 2440-2440
Author(s):  
Tian Yuan ◽  
Yaling Yang ◽  
Jeffrey You ◽  
Daniel Lin ◽  
Kefeng Lin ◽  
...  

Abstract Introduction: T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy accounting for 15% of pediatric and 25% of adult acute lymphoblastic leukemia (ALL) cases. With current chemotherapies and transplantation therapy, there are still 25-50% T-ALL patients that suffer from relapse and have a poor outcome. MicroRNAs (miRNAs or miRs) are endogenous small non-coding RNAs (containing about 22 nucleotides in length). miRs function at posttranscriptional level as negative regulators of gene expression and exert their regulatory function through binding to target mRNAs and silencing gene expression. To better understand the pathogenesis and develop the new therapeutic targets of T-ALL, we have developed a Pten tumor suppressor knockout T-ALL mouse model and profiled miRs from the mouse Pten deficient T-ALL. miR-26b was one of the miRs that were found down-regulated in the mouse Pten deficient T-ALL. Recent studies showed that the aberrant expression of miR-26b is implicated in several types of cancer. The expression level of miR-26b and its role of in T-ALL, however, are unknown. We investigated if the expression level of miR-26b is aberrant in T-ALL and the effect of potentially altered expression on the growth of human T-ALL cells. Methods: We conducted miR array profiling to identify differentially expressed miRs in the mouse Pten deficient T-ALLs compared with preneoplastic thymocyte controls. We validated expression levels of several miRs, including miR-26b, that are differentially expressed in mouse and human T-ALL cells using quantitative RT-PCR. We also overexpressed miR-26b using a lentivirus based vector in human T-ALL cell lines to assess its effect on cell growth and apoptosis. Results: Employing miR array profiling, we identified a subset of miRs that exhibited marked altered expression in the mouse Pten deficient T-ALL cells. Quantitative RT-PCR validated that the expression level of miR-26b in the mouse Pten deficient T-ALL cells was markedly lower in comparison to that of preneoplastic thymocytes. To determine if miR-26b expression level is also altered in human T-ALL, we performed quantitative RT-PCR on a panel of human T-ALL cell lines. Indeed, the expression level of miR-26b is significantly lower in the human T-ALL cell lines when compared with that of normal thymocytes. To functionally assess if miR-26b plays a role in the cell growth of human T-ALL cells, we expressed exogenous miR-26b in a panel of human T-ALL cell lines. We demonstrated that the expression of exogenous miR-26b significantly reduced the proliferation and promoted apoptosis of several human T-ALL cell lines. Conclusions: Our results demonstrated that miR-26b is down-regulated in T-ALL and the expression of exogenous miR-26b elicits deceased cell proliferation and increased apoptosis of human T-ALL. These results suggest that miR-26b may function as a tumor suppressor in the development of T-ALL and further characterization of the target and regulation of miR-26b may have therapeutic implications. Disclosures No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document